Table 3.

Intervention effects on clinical outcomes at 11-year (median) follow-up multivariate Cox proportional hazards regressions and Weibull accelerated failure time model: invasive tumor subsample only (N = 197)

Variable	Breast cancer-specific mortalitya		Breast cancer recurrenceb
	HR (95 % CI)	p	HR (95 % CI)	p
Study condition (CBSM)	0.08 (0.01–0.49)	.006	0.24 (0.07–0.82)	.011
Age at diagnosis	0.88 (0.79–0.97)	.010	0.94 (0.88–1.00)	.024
Her2/neu (positive)	4.33 (0.81–23.21)	.087	2.92 (0.97–8.77)	.039
Tumor size
>T2	7.47 (0.64–87.57)	.109	4.61 (0.82–25.82)	.062
T1c	3.61 (0.29–45.71)	.321	2.89 (0.67–22.18)	.111
<T1c	–	.266	–	–
Endocrine therapy (yes)	0.28 (0.06–1.24)	.093	0.49 (0.17–1.43)	.174
Stage (III vs. I and II)	23.46 (3.65–150.62)	.001	4.03 (1.05–15.46)	.026

HR hazard ratio, 95 % CI 95 % confidence interval, HER2/neu human epidermal growth receptor, CBSM cognitive-behavioral stress management

^aAnalyzed with Cox proportional hazards models

^bAnalyzed with Weibull accelerated failure time models